Haemonetics Co. Expected to Post Q1 2025 Earnings of $0.96 Per Share (NYSE:HAE)

Haemonetics Co. (NYSE:HAE) – Equities researchers at Zacks Research raised their Q1 2025 earnings estimates for shares of Haemonetics in a research note issued to investors on Tuesday, April 30th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will post earnings per share of $0.96 for the quarter, up from their prior estimate of $0.95. The consensus estimate for Haemonetics’ current full-year earnings is $3.95 per share. Zacks Research also issued estimates for Haemonetics’ Q2 2025 earnings at $1.06 EPS, Q3 2025 earnings at $1.09 EPS and FY2025 earnings at $4.17 EPS.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.10. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The business had revenue of $336.20 million for the quarter, compared to analysts’ expectations of $320.84 million. During the same period last year, the business earned $0.85 EPS. The company’s revenue was up 10.1% compared to the same quarter last year.

Other analysts have also recently issued reports about the stock. Barrington Research reiterated an “outperform” rating and issued a $105.00 target price on shares of Haemonetics in a research note on Friday, April 12th. TheStreet cut shares of Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th. Finally, StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd.

Haemonetics Stock Up 1.4 %

NYSE:HAE opened at $93.39 on Thursday. Haemonetics has a fifty-two week low of $70.74 and a fifty-two week high of $95.26. The stock has a market capitalization of $4.74 billion, a P/E ratio of 37.96, a P/E/G ratio of 2.17 and a beta of 0.34. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.76 and a current ratio of 2.92. The company’s 50-day simple moving average is $81.95 and its 200-day simple moving average is $82.74.

Hedge Funds Weigh In On Haemonetics

A number of institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets raised its position in Haemonetics by 6.9% during the 1st quarter. BNP Paribas Financial Markets now owns 28,971 shares of the medical instruments supplier’s stock worth $2,473,000 after buying an additional 1,874 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Haemonetics by 1.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 23,302 shares of the medical instruments supplier’s stock worth $1,844,000 after buying an additional 428 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in Haemonetics by 132.8% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 502,993 shares of the medical instruments supplier’s stock worth $42,930,000 after buying an additional 286,897 shares during the last quarter. Principal Financial Group Inc. raised its position in Haemonetics by 3.8% during the 1st quarter. Principal Financial Group Inc. now owns 211,677 shares of the medical instruments supplier’s stock worth $18,067,000 after buying an additional 7,713 shares during the last quarter. Finally, Peregrine Capital Management LLC raised its position in Haemonetics by 22.0% during the 1st quarter. Peregrine Capital Management LLC now owns 134,603 shares of the medical instruments supplier’s stock worth $11,488,000 after buying an additional 24,290 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.